The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.
The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...
The FDA cleared the investigational new drug application for LTZ-301, a first-in-class myeloid engager immunotherapy, with a ...
AIM ImmunoTech (AIM) announced that Paul Goepfert, MD, of the University of Alabama-Birmingham, has agreed to act as the Principal Investigator ...
FDA clears LTZ's IND application to initiate trial of its myeloid engager immunotherapy to treat relapsed or refractory non-Hodgkin lymphoma.
Shares of Compass Therapeutics (NASDAQ:CMPX) were up 8% in afternoon trading Monday after Guggenheim initiated coverage of ...
Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: “I’m excited for the opportunity to follow-up on my previous work regarding the combination of Ampligen and FluMist, ...
The Food and Drug Administration granted fast track designation to AUTX-703 for relapsed or refractory acute myelogenous ...
Zabalafin Hydrogel is a novel, first-in-class complex single-source botanical drug with multiple bioactive compounds that provide multiple mechanisms of action, including anti-pruritic (anti-itch ...